TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Active CounterACT Researchers & Projects


CounterACT: Countermeasures Against Chemical Threats - banner graphic

Research @ NIH
CounterACT
Scientific Contacts
David A. Jett, Ph.D.
Program Director
Phone: 301-496-6035
jettd@ninds.nih.gov

D. Yeung, Ph.D.
Project Manager
Tel: 301-443-7534
dy70v@nih.gov

CounterACT network map

Abstracts, budgets, and contact information for all CounterACT-supported  projects are available via the NIH RePORTER database


Research Centers of Excellence (U54)

UMDNJ/Rutgers University CounterACT Research Center of Excellence 
Jeffrey D. Laskin, Ph.D.
RBHS - Robert Wood Johnson Medical School
U54AR055073

Novel Therapeutics for Vesicant and Toxic Inhaled Chemicals   
Carl W. White, M.D.
University of Colorado, Denver
U54ES015678

Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication 
Pamela J. Lein, Ph.D.
University of California, Davis
U54NS079202

A Discovery and Development Pipeline for Cyanide Countermeasures
Calum A. MaCrae, M.D., Ph.D.
Brigham and Women's Hospital
U54NS079201
 


Individual Research Projects (U01)

Preclinical and Clinical Studies of Cobinamide, a New Cyanide Detoxifying Agent 
Gerry R. Boss, M.D.  
University of California, San Diego
U01NS058030

Efficacy of GluR5 Antagonists Against Soman-Induced Seizures and Neuropathology 
Maria F.M. Braga, D.D.S., Ph.D.
Uniformed Services University of the Health Sciences
U01NS058162

Parathion Exposure: Mechanisms of Toxicity and Treatment 
Robert J. DeLorenzo, M.D., Ph.D., M.P.H.  
Virginia Commonwealth University
U01NS058213

Prostanoid Modulators that Reduce Brain Injury After Seizures 
Raymond J. Dingledine, Ph.D.
 
Emory University School of Medicine
U01NS058158

Novel Therapies for Chlorine-Induced Lung Injury 
Gary W. Hoyle, Ph.D.    
University of Louisville
U01ES015673

Targeting Injury Pathways to Counteract Pulmonary Agent and Vesicant Toxicity 
Sven-Eric Jordt, Ph.D.
Yale University
U01ES015674

Functional Genomics of Chemical -Induced Acute Lung Injury 
George D. Leikauf, Ph.D.    
University of Pittsburgh
U01ES015675

Induced Therapeutic Overexpression of Acetylcholinesterase in vivo 
Richard L. Rotundo, Ph.D.   
University of Miami Miller School of Medicine
U01NS057994
 
Rational Polytherapy in the Treatment of Cholinergic Seizures 
Claude G. Wasterlain, M.D.
Brentwood Medical Research Institute
U01NS074926
 

Effective Therapies for Ocular Injuries by Vesicating Agents 
Rajesh Agarwal, Ph.D.
University of Colorado Health Sciences Center
U01EY023143

Development of Therapeutics for Chlorine-induced Airway and Lung Injury 
Michael D. Gunn, M.D.
Duke University Medical Center 
U01ES017219

Countermeasures for Chlorine-Induced Airway Fibrosis 
Gary W. Hoyle, Ph.D.    
University of Louisville
U01ES022564

Amelioration of Vesicant-Induced Skin Injury by High Dose 25-Hydroxyvitamin D 
Kurt Lu, M.D.
Case Western Reserve University 
U01AR064144


Pharmacotherapy to CounterACT Parathion-induced NMJ Dysfunction 
Steven B. Bird, M.D.
University of Massachusetts Medical School 
U01NS083452

Intralipid: A Novel Frontline Countermeasure for Brodifacoum Poisoning
Douglas L. Feinstein, Ph.D.  
University of Illinois
U01NS083457

Improved Standard of Care Reactivators and Facilitative Transport into the Central Nervous System
Gregory E. Garcia, Ph.D.  
U.S. Army Medical Research Institute of Chemical Defense
U01NS083448

Developing Drugs to Mitigate Parathion Intoxication
Jeffrey D. Laskin, Ph.D.
RBHS-Roberts W. Johnson Medical School
U01NS079249

Neuroprotective Effects of AEOL 10150 Against Organophosphate Toxicity
Manisha N. Patel, Ph.D.
University of Colorado, Denver
U01NS0883422

Nitrite Dependent Protection Against Cl2 Gas Toxicity Role of Chlorinated Lipids
Rakesh Patel, Ph.D.
University of Alabama, Birmingham
U01ES023759

Neurosteroid Treatment for OP Intoxication
Doodipala S. Reddy, Ph.D.
Texas A&M University Health Science Center
U01NS083460

 

Extracellular RNA as Therapeutic Target After Toxic Chemical Inhalation
Aftab Ahmad, Ph.D.
University of Alabama, Birmingham
U01ES025069

Brain-Penetrating Acetylcholinesterase Reactivators for Several Organophophates
Janice E. Chambers, Ph.D.
Mississippi State University
U01NS083430

Reactivation of Aged Acetylcholinesterase: Design and Development of Novel Therapeutics against Exposure to Organophosphorus Chemical Nerve Agents
Christopher Hadad, Ph.D.
Ohio State University
U01NS087983

Accelerate AChE Reactivator Design by Mechanistic Neutron Scattering Studies
Zoran Radic, Ph.D.
University of California San Diego
U01NS083451

Thioredoxin Mimicry: Novel Treatment of Toxicant-mediated Inhalational Lung Injury
Garry J. Southan, Ph.D.

Radikal Therapeutics, Inc.
U01ES024097

 

Blocking Arsenicals-induced Cutaneous Injury
Mohammad Athar, Ph.D.
University of Alabama at Birmingham
U01NS095678

Development of the Vitamin B12 Analog Cobinamide as a Hydrogen Sulfide Antidote
Gerry R. Boss, M.D.
University of California San Diego
U01NS087964

Bromine Inhalation Induced Lung Injury: Novel Mechanisms and Treatment Strategies
Sadis Matalon, Ph.D.
University of Alabama at Birmingham
U01ES026458

Molecular Imaging of Chemical Threats and Countermeasures
Charles M. Thompson, Ph.D.
University of Montana Missoula
U01NS092495
 


Active Small Business Innovation Research (SBIR) 

Definitive Studies for Use of Galantamine as a Pre-treatment Countermeasure Against Nerve Agent Poisoning 
William Basinger, Jr., M.S.
CounterVail Corporation
R44NS068049

Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatment
Yvonne Rosenberg, Ph.D.
Plantvax, Inc.
R44NS064608

Development of a Field-Deployable Device to Rapidly Measure Blood Cyanide Levels
Hans Boehringer, Ph.D.
Diagnostic Consulting Network, Inc.
R44NS076359

 


Exploratory/Developmental Projects (R21)

Formulation and Encapsulation of Enzyme Countermeasures Against Organophosphorus Compounds
Thomas J. Magliery, Ph.D.
Ohio State University
R21NS084899


Screening Therapies to Counteract Developmental Chlorpyrifos Intoxication
Jared Goldstone, Ph.D.
Woods Hole Oceanographic Institution
R21NS084897

Methylene Blue, A Novel Treatment of H2S Poisoning-induced Brain Injury
Philippe Haouzi, M.D.
Pennsylvania State University Hershey Medical Center
R21NS090017

Central Role of Heme Oxygenase in Reversing Bromine Morbidity and Mortality
Sadis Matalon, Ph.D.
University of Alabama at Birmingham
R21ES025423

Cyanide Decorporation by Co(III) Schiff-base Macrocycles
Linda Pearce, Ph.D.
University of Pittsburgh
R21NS089893

Efficacy of Cobinamide for Treatment of Hydrogen Sulfide-induced Neurotoxicity
Wilson Rumbeiha, Ph.D.
Iowa State University of Science and Technology
R21NS089487

Developing and Evaluating Countermeasures Against Tetramethylenedisulfotetramine
Michael Shakarjian, Ph.D.
New York Medical College
R21NS084900

 


Contracts, Inter-Agency Agreements, and Other Resources

CounterACT Preclinical Development Facility (CPDF) 
Carol Green, Ph.D., D.A.B.T.
  
SRI International
N01NS62369

Interagency Agreements (IAAs) between the National Institutes of Health and the Department of Defense
Chemicals Affecting Skin, Eyes & Mucous Membranes - Toxic Vesicants and Industrial Chemicals
Chemicals Affecting the Nervous System - Anticonvulsants and Neuroprotectants
Cyanide Diagnostics and Efficacy Testing of Next Generation Cyanide Antidotes
Chemicals Affecting the Respiratory Tract - Pulmonary Toxicants
James F. Dillman, Ph.D.
  
U.S. Army Medical Research Institute of Chemical Defense 
 

Last updated July 30, 2015